Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGORAC: Tacrolimus Minimization in Kidney Transplant Recipients
NCT06235892Phase 3Recruiting
- Sponsor
- CHU de Nantes
- Start
- Dec 2024
- Primary completion
- Jun 2028
- Modality
- RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplantation (2 arms), sponsored by CHU de Nantes. Primary endpoint: Improvement of the renal function at 18 months. Started Dec 2024; status: recruiting.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT06235892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235892.